Physicians Learn About Multiple Myeloma and MGUS on Webcast

OSUWexnerbloglogo2014 Physicians Learn About Multiple Myeloma and MGUS. Today on MedNet, we’re going to update you on the newest developments in the management of multiple myeloma. We’re pleased to welcome Assistant Professor of Internal Medicine, Dr. Srinivas Devarakonda.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: explain the clinical scenarios in which to suspect multiple myeloma; Explain the diagnostic methods for multiple myeloma; discuss the latest diagnostic criteria and staging system for multiple myeloma; and describe the management of myeloma.

You’ll also learn about the following:

  • Multiple myeloma demographics
  • Multiple myeloma prognosis
  • Evaluation of MGUS
  • When to replace patients with IgG
  • Screening for multiple myeloma
  • Waldenstrom’s macroglobulinemia
  • Kappa versus lambda light chains
  • Future directions in treatment

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line CME Discussing Multiple Myeloma

OSUWexnerbloglogo2014 On-line CME Discussing Multiple Myeloma. In the past year, there have been 4 new drugs approved to treat multiple myeloma and these are changing the way that we manage patients with this disease. On this CME webcast, we’re going to talk about what multiple myeloma is, how you diagnosis it, and how it is treated. Joining our moderator in the studio is hematologist and Assistant Professor of Internal Medicine from the OSU Wexner Medical Center, Dr. Ashley Rosko. And also from the division of hematology, we have Associate Professor of Internal Medicine, Dr. Yvonne Efebera joining us.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the difference between MGUS, smoldering Myeloma, Symptomatic multiple Myeloma; DESCRIBE the general clinical features of plasma cell myeloma including the diagnosis, and steps required for evaluation; UNDERSTAND Treatment strategy for Newly diagnosed Multiple Myeloma Patients Eligible for Transplant and Newly diagnosed Multiple Myeloma Patients not Eligible for Transplant.

You’ll also learn about the following:

  • Epidemiology of multiple myeloma
  • Prognosis of multiple myeloma
  • When to do a bone marrow biopsy?
  • Screening patients with kidney failure for multiple myeloma
  • Management of hypercalcemia and renal failure in multiple myeloma
  • Autologous versus allogenic stem cell transplant

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.